Sun Life Financial Movement Disorders Research and Rehabilitation Centre, Wilfrid Laurier University, ON, Canada.
J Parkinsons Dis. 2012;2(3):207-13. doi: 10.3233/JPD-2012-012093.
The Unified Parkinson's Disease Rating Scale (UPDRS) is the gold standard for assessing Parkinsonian symptoms, yet objective outcome measures are needed to complement the UPDRS in research and clinical practice.
This study aimed to investigate the relationship between performance on the Grooved Pegboard Test (GP) and clinical assessment of Parkinson's motor symptoms with the UPDRS.
A large sample of individuals with Parkinson's disease (n = 191) were assessed with the GP and UPDRS motor section. The GP was separated into a place (more representative of visuospatial accuracy) and remove phase (general representation of motor speed and bradykinesia). Both tests were completed at peak anti-parkinsonian medication levels, and UPDRS subscores were calculated to represent upper-limb control, rigidity, bradykinesia, and tremor. A subsequent correlation analysis was completed.
The strongest relationships were between the GP place phase (both limbs) and total UPDRS motor score (affected: r = 0.604, less-affected: r = 0.587), upper-limb control (affected: r = 0.367, less-affected: r = 0.426), rigidity (affected: r = 0.479, less-affected: r = 0.457) and body bradykinesia (affected: r = 0.375, less-affected: r = 0.438). The GP remove phase had weak positive relationships with total UPDRS scores (affected: r = 0.31, less-affected r = 0.31) and body bradykinesia (r = 0.31).
Clinical assessment of upper-limb control, rigidity and bradykinesia are well represented by the GP place phase. Interestingly, it appeared that GP performance of the more affected limb may be more representative of motor severity in the early stages of disease, while more research is needed to understand the utility of the GP in the advanced stages of disease.
统一帕金森病评定量表（UPDRS）是评估帕金森病症状的金标准，但在研究和临床实践中需要客观的结果测量来补充 UPDRS。
本研究旨在探讨在帕金森病患者中，使用格雷夫斯棒测试（GP）评估与 UPDRS 运动评分的关系。
对 191 名帕金森病患者进行 GP 和 UPDRS 运动部分的评估。GP 测试分为放置（更代表视空间准确性）和移除（一般代表运动速度和运动迟缓）两个阶段。这两个测试都在抗帕金森药物的峰值水平下完成，UPDRS 子评分代表上肢控制、僵硬、运动迟缓、震颤。随后进行相关性分析。
最强的相关性存在于 GP 放置阶段（双侧）和 UPDRS 运动总分（受累侧：r = 0.604，非受累侧：r = 0.587）、上肢控制（受累侧：r = 0.367，非受累侧：r = 0.426）、僵硬（受累侧：r = 0.479，非受累侧：r = 0.457）和身体运动迟缓（受累侧：r = 0.375，非受累侧：r = 0.438）。GP 移除阶段与 UPDRS 总分（受累侧：r = 0.31，非受累侧：r = 0.31）和身体运动迟缓（r = 0.31）呈弱正相关。
上肢控制、僵硬和运动迟缓的临床评估由 GP 放置阶段很好地代表。有趣的是，在疾病的早期阶段，更受累侧的 GP 表现可能更能代表运动严重程度，而需要更多的研究来了解 GP 在疾病晚期的应用。
